Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants이종 Chadox1 NCOV-19 및 BNT162B2 프라임-부스트 백신 접종은 유능한 SARS-COV-2 변이체에 대한 강력한 중화 항체 반응 및 T 세포 반응성을 유도합니다.Clinical Trial Published on 2021-12-172022-08-13 Journal: EBioMedicine [Category] SARS, 변종, 임상, 진단, [키워드] addition Administered Adverse reactions All participants Alpha analysed antibody titres ART Arts B.1.1.7 B.1.351 B.1.617.1 B.1.617.2 Beta BNT162b2 boost CD4 CD8 Cellular immune response cellular immune responses ChAdOx1 ChAdOx1 nCoV-19 Cohort Course COVID-19 COVID-19 vaccination Delta dominant elicit elicited European evaluate finding followed by foundation funding Gamma Germany Heterologous heterologous vaccination homologous Horizon humoral immune immune responses Immunity immunogenic Immunological response immunological responses individual induce Lower median mRNA-based vaccine mRNA-based vaccines nCoV neutralization neutralized Neutralizing activity Neutralizing antibody response no difference offer P.1 participant peptide peptides prevalent Protective reactive reactivity reactogenicity receiving recognize regimen Research resulting retained Robert Koch SARS-CoV-2 spike peptide SARS-CoV-2 variant SARS-CoV-2 variants Science sera Serious Adverse Event Serious Adverse Events serological data significantly Symptom T cell T cells tested titre union vaccination variant variants variants of concern Wuhan Wuhan-Hu-1 [DOI] 10.1016/j.ebiom.2021.103761 PMC 바로가기 [Article Type] Clinical Trial
Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic in self-reported good and poor sleepers (Sleep COVID-19): study protocol for a randomised controlled trialCOVID-19 대유행 동안 수면 장애 치료를 위한 조기 온라인 중재 테스트(수면 COVID-19): 무작위 통제 시험을 위한 연구 프로토콜Update Published on 2021-12-112022-09-10 Journal: Trials [Category] SARS, 임상, [키워드] Acute insomnia administration All participant All participants analysed approach assigned Baseline assessment baseline assessments behavioural can be used Cognitive behavioural therapy Complete COVID-19 COVID-19 pandemic disorder effective enrolled events expected face-to-face therapy feasibility Good include individuals Insomnia Insomnia Severity Index intention-to-treat Intervention intervention group leaflet life Online intervention outcome measure participant Poor post intervention Prevent primary outcome measure problem randomised controlled trial Randomly receive reduce Registered secondary secondary outcome measures severity short-term disruptions Sleep Sleep disturbances Specific stratified Stress Study protocol Symptom Testing transition treat Treatment [DOI] 10.1186/s13063-021-05888-0 PMC 바로가기 [Article Type] Update
Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults노인에서 COVID-19 mRNA 백신에 대한 체액성 면역 반응의 크기 및 내구성 감소Major Article Published on 2021-12-092022-09-10 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ACE2 activity Adults age All participants antibodies antibody binding antibodies binding antibody characterized correction COVID-19 COVID-19 mRNA vaccine COVID-19 mRNA vaccines declined delta variant elevated evaluated except for exhibited health condition healthcare worker humoral humoral immune response Humoral response humoral responses immune response immune responses magnitude measure mRNA vaccine mRNA vaccines Neutralizing activity Older older adult Older adults Older age Participants plasma RBD reduced remained response Result risk of infection second dose significantly significantly lower sociodemographic factors tested vaccination vaccine dose variables viral neutralization virus were assessed [DOI] 10.1093/infdis/jiab592 PMC 바로가기 [Article Type] Major Article
The Impact of COVID-19 on Risky Behaviors and Health Changes in African-American Smokers Who Are Eligible for LDCT ScreeningLDCT 선별 검사를 받을 수 있는 아프리카계 미국인 흡연자의 위험한 행동 및 건강 변화에 대한 COVID-19의 영향Public Health Published on 2021-12-082022-09-11 Journal: Frontiers in Public Health [Category] SARS, 치료기술, [키워드] activity adverse outcome adverse outcomes African American (AA) age All participants Anxiety Behavior body weight change changes in cigarette smoking Computed tomography COVID-19 COVID-19 pandemic demographics Descriptive statistics dose eligible female fruits Health Health status healthy behavior higher risk Impact impacted income Increased stress information investigated LDCT lung cancer screening less life management Medicaid pandemic participant participated physical activity reported Result risky behavior Screening smoker Smokers smoking smoking cessation Stress were used [DOI] 10.3389/fpubh.2021.745925 PMC 바로가기 [Article Type] Public Health
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and EfavirenzCYP2B6 Dolutegravir와 Efavirenz의 유전자형 및 체중 증가 차이Online Only Articles Published on 2021-12-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] All participants Antiretroviral therapy ARMS ART baseline baseline CD4 baseline characteristics changes in Characteristics concentrations CYP2B6 difference dolutegravir dual-energy x-ray absorptiometry DXA efavirenz emtricitabine explain fat fumarate Gain Genotype genotyping greater HIV-1 Human immunodeficiency virus impair impaired weight men participant PLWH polymorphism Randomized Result RNA tenofovir tenofovir disoproxil fumarate variable weight weight gain women [DOI] 10.1093/cid/ciaa1073 PMC 바로가기 [Article Type] Online Only Articles
Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial내성 주요 우울 장애의 치료를위한 psilocybin- 보조 요법 (PSIDER) : 무작위, 위약 대조 타당성 시험의 프로토콜Mental Health Published on 2021-12-012022-09-10 Journal: BMJ Open [Category] Fulltext, SARS, 임상, [키워드] adult psychiatry All participant All participants Analysis Biomarker blinded clinical trials collected CTA Depression depression & mood disorders depressive depressive disorder disorder dissemination dose dropout rate Ethics ethics committee extension feasibility Follow-up Health Research Authority Healthcare Products Regulatory Agency independent London major depressive disorder measure mechanism media National Research Ethics Committee Neuroimaging occur offer open open label package parallel-group participant peer-reviewed Placebo placebo-controlled primary endpoint Primary outcome primary outcome measure Primary outcomes product protocol psilocybin psychological therapy randomised receive recruitment registration numbers required Research Ethics scale therapy Treatment Trial trials variance written Informed Consent [DOI] 10.1136/bmjopen-2021-056091 PMC 바로가기 [Article Type] Mental Health
Waning immunity six months after BioNTech/Pfizer COVID-19 vaccination among nursing home residents in Zagreb, Croatia크로아티아 자그레브의 요양원 거주자의 BioNTech/Pfizer COVID-19 백신 접종 후 6개월 만에 면역력 약화Short Communication Published on 2021-12-012022-09-10 Journal: Croatian Medical Journal [Category] SARS, 치료기술, [키워드] All participant All participants Antibody titer booster dose contribute correlated COVID-19 COVID-19 patient COVID-19 vaccination Croatia defined dose enrolled had no highest Humoral immunity Immunity IQR Mann-Whitney Mann-Whitney U median titer men neutralization neutralization test Neutralizing antibodies neutralizing antibody Neutralizing antibody titer nursing home participant positive Research Result SARS-COV-2 infection SARS-CoV-2 strain serum dilution significantly significantly higher Spearman tested vaccination Vero E6 Vero E6 cell VERO E6 cells virus virus neutralization test was used [DOI] 10.3325/cmj.2021.62.630 PMC 바로가기 [Article Type] Short Communication
Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine비활성화된 SARS-CoV-2 백신에 대한 인간 IgM 및 IgG 반응Article Published on 2021-12-012022-09-11 Journal: Current medical science [Category] MERS, SARS, 진단, 치료기술, [키워드] accelerated age All participant All participants all subjects anti-IgG antibody Antibody Response Antibody responses COVID-19 COVID-19 pandemic defined dose dose of vaccination Effects effort elicited Factor female for inclusion had no healthy individuals Human IgG antibodies IgG antibody IgM IgM and IgG IgM and IgG antibody responses in healthy individual inactivated inactivated SARS-CoV-2 vaccine. individual less male no effect Older positive result recipients response Retrospective study SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine second dose seropositive significantly higher significantly lower subject vaccination vaccine candidates were assessed [DOI] 10.1007/s11596-021-2461-8 PMC 바로가기 [Article Type] Article
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial건강한 소아 및 청소년을 대상으로 한 불활성화 SARS-CoV-2 백신(CoronaVac)의 안전성, 내약성 및 면역원성: 이중 맹검, 무작위, 대조, 1/2상 임상 시험Clinical Trial Published on 2021-12-012022-09-12 Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] 95% CI Adverse reaction age All participants aluminum Antibody Response Antibody titre assigned Beijing block Block randomisation center children China Chinese clinical trial Control CoronaVac COVID-19 pandemic COVID-19 vaccine detectable development dose dose-escalation double-blind Endpoint enrolled geometric mean titre groups healthy children Humoral response hydroxide inactivated individual Infection injection injection site Intramuscular injection investigators Laboratory live SARS-CoV-2 Mild moderate MOST neutralising antibody occurred Pain participant Participants per-protocol population phase 1 trial Pneumonia prevention primary immunogenicity Program randomised Randomly receive Registered reported Safe Safety safety population safety profile SARS-CoV-2 SARS-CoV-2 vaccine Science second dose Serious Adverse Event Seroconversion seroconversion rate severity significant difference Support technology three group Tolerability vaccination Vaccine were excluded [DOI] 10.1016/S1473-3099(21)00319-4 PMC 바로가기 [Article Type] Clinical Trial
Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced ImmunityBNT162b2 SARS-CoV-2 백신 유도 면역의 알파 및 베타 변이체에 대한 중화의 연령 의존적 감소Research Article Published on 2021-12-012022-09-10 Journal: Microbiology Spectrum [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 age All participants anti-RBD antibody antibody level antibody levels Antibody test Antigen basic Beta binding domain BNT162b2 BNT162b2 vaccine Clinical characteristics collected Coronavirus-2 correlated Cutoff decrease female groups Health care Health care worker health care workers heterogeneity high risk higher risk Humoral immunity Immunity include individual Infection interquartile range introduced IQR median mRNA vaccine mRNA vaccines neutralization Neutralizing Neutralizing activity Neutralizing antibodies of BNT162b2 Older age participant Patient patient age positive Pseudotyped virus questionnaire Questionnaires Randomly Receptor-binding domain reduction respiratory SARS-CoV-2 SARS-COV-2 infection second dose selected sera serum dilution Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Spike protein Toyama U/mL university vaccination variant variants Viral viral variant Viral variants virus viruses was obtained were measured wild type wild-type wild-type SARS-CoV-2 wild-type virus [DOI] 10.1128/Spectrum.00561-21 PMC 바로가기 [Article Type] Research Article